Neoadjuvant Systemic Chemotherapy in Sebaceous Gland Carcinoma of the Eyelid: A Retrospective Study

Overview

Journal Ocul Oncol Pathol

Date 2021 Oct 4

PMID 34604196

Citations 5

Authors

Saurav Verma

Nipun Kumar

Rachna Meel

Seema Sen

Seema Kashyap

Sanjay Sharma

Neelam Pushker

Deepam Pushpam

Sameer Bakhshi

Affiliations

Soon will be listed here.

Abstract

There are sparse data on neoadjuvant systemic chemotherapy (NACT) in eyelid sebaceous gland carcinoma (SGC). The aim of this study was to evaluate efficacy and outcomes with NACT in eyelid SGC. We retrospectively analyzed 8 patients who received platinum-based NACT. The median number of cycles per patient was 4 (range, 3-5). The mean percentage reduction of tumor diameter after NACT was 71% (range, 30-100%). Two patients had a radiological complete response (CR). After NACT, surgical treatment for residual tumor was performed in 5 cases. One patient had a pathological CR and is recurrence free for 11 years. After a mean follow-up period of 44.5 months (range, 9-109), tumor recurrence occurred in 4 cases. Among these 4 cases, 3 were rechallenged with the same regimen and all responded. Systemic NACT has a role in eyelid SGC, downstages the tumor, and allows less aggressive and organ-sparing surgeries, warranting a prospective study.

Citing Articles

Multimodal treatment with Neoadjuvant chemotherapy for eyelid and periocular sebaceous gland carcinoma: Long-term outcomes.

Vempuluru V, Luthra A, Palkonda V, Kaliki S Am J Ophthalmol Case Rep. 2025; 38:102272.

PMID: 40028471 PMC: 11869872. DOI: 10.1016/j.ajoc.2025.102272.

Molecular landscape of eyelid sebaceous gland carcinoma: A comprehensive review.

Jayaraj P, Ray D, Goel K, Singh A, Kant N, Sen S Indian J Ophthalmol. 2024; 72(10):1393-1403.

PMID: 39331429 PMC: 11573021. DOI: 10.4103/IJO.IJO_167_24.

Neoadjuvant Chemotherapy in Non-Metastatic Eyelid Sebaceous Gland Carcinoma: A Report in 10 Cases.

Kumar N, Meel R, Bakhshi S, Pushpam D, Pushker N, Bajaj M Ocul Oncol Pathol. 2024; 10(3):123-130.

PMID: 39224524 PMC: 11368394. DOI: 10.1159/000538295.

Neoadjuvant chemotherapy for advanced eyelid and periocular sebaceous gland carcinoma: a study of 25 cases.

Vempuluru V, Sinha P, Tanna V, Maniktala Y, Palkonda V, Kaliki S Int Ophthalmol. 2024; 44(1):341.

PMID: 39103677 DOI: 10.1007/s10792-024-03256-w.

Corneal melt with systemic chemotherapy in eyelid sebaceous gland carcinoma: Chemo-toxicity or tumor-necrosis-induced inflammation.

Meel R, Kumar N, Anand M, Bakhshi S Indian J Ophthalmol. 2024; 72(5):757-758.

PMID: 38648442 PMC: 11168561. DOI: 10.4103/IJO.IJO_1975_23.

References

Bhardwaj M, Sen S, Sharma A, Kashyap S, Chosdol K, Pushker N . ZEB2/SIP1 as novel prognostic indicator in eyelid sebaceous gland carcinoma. Hum Pathol. 2015; 46(10):1437-42. DOI: 10.1016/j.humpath.2015.05.026. View

Pardo F, Wang C, Albert D, Stracher M . Sebaceous carcinoma of the ocular adnexa: radiotherapeutic management. Int J Radiat Oncol Biol Phys. 1989; 17(3):643-7. DOI: 10.1016/0360-3016(89)90117-x. View

Hata M, Koike I, Omura M, Maegawa J, Ogino I, Inoue T . Noninvasive and curative radiation therapy for sebaceous carcinoma of the eyelid. Int J Radiat Oncol Biol Phys. 2011; 82(2):605-11. DOI: 10.1016/j.ijrobp.2010.12.006. View

Kaliki S, Ayyar A, Nair A, Mishra D, Reddy V, Naik M . Neoadjuvant Systemic Chemotherapy in the Management of Extensive Eyelid Sebaceous Gland Carcinoma: A study of 10 Cases. Ophthalmic Plast Reconstr Surg. 2015; 32(1):35-9. DOI: 10.1097/IOP.0000000000000398. View

Paschal B, Bagley C . Sebaceous gland carcinoma of the eyelid: complete response to sequential combination chemotherapy. N C Med J. 1985; 46(9):473-4. View

Bhardwaj M, Sen S, Chosdol K, Bakhshi S, Pushker N, Sharma A . Vimentin overexpression as a novel poor prognostic biomarker in eyelid sebaceous gland carcinoma. Br J Ophthalmol. 2019; 104(6):879-884. DOI: 10.1136/bjophthalmol-2018-313285. View

Singh L, Singh M, Rizvi M, Pushker N, Bakhshi S, Sen S . Prognostic significance of immune checkpoints in the tumour-stromal microenvironment of sebaceous gland carcinoma. Br J Ophthalmol. 2020; 105(1):48-56. DOI: 10.1136/bjophthalmol-2019-315490. View

Bhardwaj M, Sen S, Chosdol K, Sharma A, Pushker N, Kashyap S . miRNA-200c and miRNA-141 as potential prognostic biomarkers and regulators of epithelial-mesenchymal transition in eyelid sebaceous gland carcinoma. Br J Ophthalmol. 2017; 101(4):536-542. DOI: 10.1136/bjophthalmol-2016-309460. View

Yen M, Tse D, Wu X, WOLFSON A . Radiation therapy for local control of eyelid sebaceous cell carcinoma: report of two cases and review of the literature. Ophthalmic Plast Reconstr Surg. 2000; 16(3):211-5. DOI: 10.1097/00002341-200005000-00008. View

10.

Ni C, Guo B . Pathologic classification of meibomian gland carcinomas of eyelids: clinical and pathologic study of 156 cases. Chin Med J (Engl). 1979; 92(10):671-6. View

11.

Gogia A, Pushker N, Sen S, Bakhshi S . Avoidance of exenteration in orbital sebaceous gland carcinoma with neoadjuvant chemotherapy. Graefes Arch Clin Exp Ophthalmol. 2013; 251(10):2479-80. DOI: 10.1007/s00417-013-2382-8. View

12.

Dasgupta T, Wilson L, Yu J . A retrospective review of 1349 cases of sebaceous carcinoma. Cancer. 2008; 115(1):158-65. DOI: 10.1002/cncr.23952. View

13.

Murthy R, Honavar S, Burman S, Vemuganti G, Naik M, Reddy V . Neoadjuvant chemotherapy in the management of sebaceous gland carcinoma of the eyelid with regional lymph node metastasis. Ophthalmic Plast Reconstr Surg. 2005; 21(4):307-9. DOI: 10.1097/01.iop.0000169426.57497.24. View

14.

RAO N, Hidayat A, McLean I, ZIMMERMAN L . Sebaceous carcinomas of the ocular adnexa: A clinicopathologic study of 104 cases, with five-year follow-up data. Hum Pathol. 1982; 13(2):113-22. DOI: 10.1016/s0046-8177(82)80115-9. View

15.

Kaliki S, Bothra N, Bejjanki K, Nayak A, Ramappa G, Mohamed A . Malignant Eyelid Tumors in India: A Study of 536 Asian Indian Patients. Ocul Oncol Pathol. 2019; 5(3):210-219. PMC: 6489076. DOI: 10.1159/000491549. View

16.

Nelson B, Hamlet K, Gillard M, Railan D, Johnson T . Sebaceous carcinoma. J Am Acad Dermatol. 1995; 33(1):1-15; quiz 16-8. DOI: 10.1016/0190-9622(95)90001-2. View

17.

Shields J, Demirci H, Marr B, Eagle Jr R, Shields C . Sebaceous carcinoma of the ocular region: a review. Surv Ophthalmol. 2005; 50(2):103-22. DOI: 10.1016/j.survophthal.2004.12.008. View

18.

Shields C, Naseripour M, Shields J, Eagle Jr R . Topical mitomycin-C for pagetoid invasion of the conjunctiva by eyelid sebaceous gland carcinoma. Ophthalmology. 2002; 109(11):2129-33. DOI: 10.1016/s0161-6420(02)01239-3. View

19.

SWEEBE E, COGAN D . Adenocarcinoma of the Meibomian gland; a pseudochalazion entity. AMA Arch Ophthalmol. 1959; 61(2):282-90. DOI: 10.1001/archopht.1959.00940090284015. View

20.

Priyadarshini O, Biswas G, Biswas S, Padhi R, Rath S . Neoadjuvant chemotherapy in recurrent sebaceous carcinoma of eyelid with orbital invasion and regional lymphadenopathy. Ophthalmic Plast Reconstr Surg. 2010; 26(5):366-8. DOI: 10.1097/IOP.0b013e3181c32515. View